Number (%) of patients with complement activation before and normalisation after rituximab+belimumab
| C4d | C4 | C3 | Total | |
| Complement activation | ||||
| C4d | 14 | 9 (64%) | 13 (93%) | 14/15 (93%) |
| C4 | 9 (100%) | 9 | 8 (89%) | 9/15 (60%) |
| C3 | 13 (100%) | 9 (69%) | 13 | 13/15 (87%) |
| Complement normalisation | ||||
| C4d | 6 | 6 (100%) | 4 (67%) | 6/14 (43%) |
| C4 | 3 (50%) | 6 | 4 (67%) | 6/9 (67%) |
| C3 | 3 (50%) | 6 (100%) | 6 | 6/13 (46%) |
SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.